Who iCAPTUR4E Is  
      Investigator Profiles  
<< back
  Thomas J. Podor BSc., MSc., PhD.,
Associate Professor, Department of Pathology and Laboratory Medicine
Co-Director of the Dynamic Cellular Imaging and Biophysics Core
UBC McDonald Research Laboratories/iCAPTUR4E Centre
St. Paul's Hospital
Room 292, 1081 Burrard Street
Vancouver, B.C. V6Z 1Y6
Phone: 604-806-9144
Fax: 604-806-8351
e-mail: tpodor@mrl.ubc.ca


Dr. Podor earned his B.Sc. in Biology from the University of Western Ontario in 1978. He then went on to earn his M.Sc. in Physiology/Biophysics, and his Ph.D. in Pathology from the University of Southern California in 1980, and 1984, respectively. During his graduate studies Dr. Podor studies various aspects of cardiovascular pathophysiology, particularly the role of endothelial cell proteolytic enzymes in the degradation of fibrin clots and extracellular matrix components. He then moved to the Department of Immunology at Scripps Research Institute in La Jolla, CA where his research involved immunochemical and biochemical studies on the role of plasminogen activator inhibitor-1 (PAI-1) in thrombosis and fibrin clot degradation (fibrinolysis). In 1989, he moved back to Canada and began developed his research program in thrombosis and thrombolysis at McMaster University.

Dr. Podor's effort to develop new approaches to remove blood clots through enzymatic and/or mechanical approaches lead him to consider both the biochemistry and structure of blood clots. His multidisciplinary research involved (i) studying the effects of inflammatory mediators on endothelial cell and platelet regulation of fibrinolysis in various in vitro and in vivo models of thrombosis and vascular injury, and (ii) defining the specific binding interactions and spatial distribution of PAI-1, vitronectin, t-PA, and other components in blood clots, damaged blood vessels, myocardium, and other tissues. His research has lead him to investigate further the role of PAI-1, vitronectin, t-PA in the repair and remodeling of hearts damaged by ischemia/infarction, infections, or transplantation. Thus, to facilitate his studies on damaged hearts, he moved his laboratory in July 2002 to the McDonald Research Laboratories (MRL) and iCAPTUR4E Centre at St. Paul's Hospital/ University of British Columbia. Since arriving, Dr. Podor has also developed a new line of research involving the use of autologous bone marrow-derived stem cells to repair and regenerate the damaged myocardium, and to use these stem cells as a means of introducing cardioprotective transgenes (e.g., t-PA) into the damaged heart. Much of his work has involved the use of laser confocal scanning microscopy to visualize the distribution of fluorescently labeled proteins and cells in tissues. His new laboratory is equipped with state-of-the-art confocal and two-photon microscopy facilities suited for advancing three- and four-dimensional imaging technology for studying cardiovascular disease, and developing animal models for testing new methods of treating thrombosis, defects in fibrinolysis, and regenerating damaged myocardium

Recent Publications:

1. Seiffert D, Geisterfer M, Gauldie J, Young E and Podor TJ. Interleukin-6 Stimulates Vitronectin Gene Expression In Vivo. J Immunol 155(6): 3180-3185, 1995.

2. Hill SA, Shaughnessy SG, Joshua P, Ribau J, Austin RC and Podor TJ. Differential Mechanisms Targeting Type 1 Plasminogen Activator Inhibitor and Vitronectin into the Storage Granules of a Human Megakaryocytic Cell Line. Blood 87(12): 5061-5073, 1996.

3. Torry DJ, Richards CD, Podor TJ and Gauldie J. Modulation of the Anchorage-Independent Phenotype of Human Lung Fibroblasts Obtained from Fibrotic Tissue Following Culture with Retinoid and Corticosteroid. Exp Lung Res 22(2): 231-244, 1996.

4. Young E, Podor TJ, Venner T and Hirsh J. Induction of the Acute-Phase Reaction Increases Heparin-Binding Proteins in Plasma. Arterioscler Thromb Vasc Biol 17(8): 1568-1574, 1997.

5. Wells MJ, Hatton MWC, Hewlett B, Podor TJ, Sheffield WP and Blajchman MA. Cytokeratin 18 is Expressed on the Hepatocyte Plasma Membrane Surface and Interacts with Thrombin-Antithrombin Complexes. J Biol Chem 272(45): 28574-28581, 1997.

6. Manson L, Weitz JI, Podor TJ, Hirsh J and Young E. The Variable Anticoagulant Response to Unfractionated Heparin In Vivo Reflects Binding to Plasma Proteins Rather than Clearance. J Lab Clin Med 130(6): 649-655, 1997.

7. Outinen PA, Sood SK, Liaw PCY, Sarge KD, Maeda N, Hirsh J, Ribau J, Podor TJ, Weitz JI and Austin RC. Characterization of the Stress-Inducing Effects of Homocysteine. Biochem J 332(Pt.1): 213-221, 1998.

8. Hayward CPM, Cramer EM, Song Z, Zheng S, Fung R, Masse J-M, Stead RH and Podor TJ. Studies of Multimerin in Human Endothelial Cells. Blood 91(4): 1304-1317, 1998.

9. Outinen PA, Sood SK, Pfeifer SI, Pamidi S, Podor TJ, Li J, Weitz, JI and Austin RC. Homocysteine-Induced Endoplasmic Reticulum Stress and Growth Arrest Leads to Specific Changes in Gene Expression in Human Vascular Endothelial Cells. Blood 94(3):959-967, 1999.

10. Young E, Hirsh J, Shaughnessy S, Ribau J, Venner T and Podor TJ. The Binding of Unfractionated Heparin and Low Molecular Weight Heparin to Thrombin Activated Human Endothelial Cells. Thromb Res 96(5):373-381, 1999.

11. Podor TJ, Peterson CB, DA Lawrence, Stefansson, S, Shaughnessy, SG, Foulon, DM, Butcher, M, and Weitz, JI. Type 1 Plasminogen Activator Inhibitor Binds to Fibrin via Vitronectin. J Biol Chem 275(26):19788-19794, 2000.

12. Podor, TJ, Shaughnessy, SG, Blackburn, MN, and Peterson, CB. New Insights into the Size and Stoichiometry of the Vitronectin: PAI-I Complex.. J Biol Chem 275(33):25402-25410, 2000.

13. Gyorffy, S, Palmer, K, Podor, TJ, Hitt, M, and Gauldie, J. Combined Treatment of a Murine Breast cancer Model with the Ad-5 Adenovirus Vectors Expressing Angiostatin and Interleukin-12: A Role of Combined Anti-Angiogenesis and Immunotherapy. J. Immunol., 166: 6212-6217, 2001.

14. Kahr, WHA, Zheng, S, Sheth, P, Pai, M, Cowie, A, Bouchard, M, Podor, TJ, Rivard, GE, and Hayward, CPM. Platelets from Individuals with the Quebec Platelet Disorder Contain and Secrete Abnormal Amounts of Urokinase-Type Plasminogen Activator. Blood, 98: 257-265, 2001.

15. Podor, TJ, Campbell, S, Chindemi, P, Farrell, D, Walton, PR, Weitz, JI, and Peterson, CB. Incorporation of Vitronectin into Fibrin Clots: Evidence for an Interaction between Vitronectin and gamma A/gamma' fibrinogen. J Biol Chem, 77(9):7520-7528, 2002.

16. Podor, TJ, Singh, D, Foulon, DM, Chindemi, P, McKelvie, RM, Austin, R, Boudreau, G, and Davies, R. Vimentin exposed on Activated Platelets and Platelet Microparticles Localizes Vitronectin and Plasminogen Activator Inhibitor Complexes on their Surface. J Biol Chem, 77(9): 7529-7539, 2002.


Copyright 2006, iCAPTURE.ca
Back to home Providence Health Care


Providence Health Care University of British Columbia